Curated News
By: NewsRamp Editorial Staff
September 15, 2026
Quantum BioPharma to Present at ArcStone-Kingswood Growth Summit
TLDR
- Quantum BioPharma's FDA-approved Lucid-MS Phase 2 trial for progressive MS gives investors a first-in-class edge in neurodegenerative treatment.
- Quantum BioPharma will present at the ArcStone-Kingswood Growth Summit on Sept. 16, 2026, detailing its Lucid-MS program and strategic milestones.
- Quantum BioPharma's Lucid-MS aims to reverse myelin damage, potentially improving lives for those with multiple sclerosis and other disorders.
- Quantum BioPharma also owns 19.84% of Unbuzzd, earning a 7% royalty on sales until reaching $250 million.
Impact - Why it Matters
This news matters because Quantum BioPharma’s participation in the ArcStone-Kingswood Growth Summit provides a platform to showcase its recent FDA approval for Lucid-MS Phase 2 trials, a critical milestone for a first-in-class multiple sclerosis treatment. With progressive MS patients having limited options, Lucid-MS could address a significant unmet need. Moreover, the company’s royalty agreement with Unbuzzd offers a potential long-term revenue stream, and its innovative pipeline in neurodegenerative and metabolic disorders positions it as a player to watch in the biotech sector. Investors and patients alike should take note of these developments as they could lead to new therapeutic options and value creation.
Summary
Quantum BioPharma Ltd., a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, will participate in the 3rd Annual ArcStone-Kingswood Growth Summit on Sept. 16, 2026, in Toronto. Co-founder and Executive Co-chairman Anthony Durkacz will present the company’s recent milestones and future growth strategy. The company recently announced that the U.S. Food and Drug Administration approved its Investigational New Drug application for Lucid-MS, allowing it to begin Phase 2 trials of its patented, first-in-class multiple sclerosis program in patients with progressive MS. This is a significant step for Quantum BioPharma (NASDAQ: QNTM), which is dedicated to building a portfolio of innovative assets and biotech solutions for challenging disorders.
Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum focuses on Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum also invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd and is entitled to royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The announcement was disseminated via MissionIR, a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, visit www.MissionIR.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma to Present at ArcStone-Kingswood Growth Summit
